The Association of Statin Therapy with Incident Diabetes: Evidence, Mechanisms, and Recommendations

Current Cardiology Reports
A AgarwalaT Maddox

Abstract

Recent studies have demonstrated a higher risk of incident diabetes associated with statin use, causing concern among patients and clinicians. In this review, we will assess the evidence and proposed mechanisms behind statin therapy and its association with incident diabetes. We will then review the current recommendations for statin use in light of this association and suggest next steps for clinicians managing these patients and researchers exploring this phenomenon. The annual risk of developing new-onset diabetes with statin treatment is approximately 0.1%. In comparison, the absolute risk reduction of major coronary events with statin use is approximately 0.42% annually. Statins are associated with the development of incident diabetes, particularly among those with predisposing risk factors for diabetes. However, the benefit of statin use among these patients in preventing major coronary events strongly favors statin use despite its risk of incident diabetes.

References

Dec 5, 1998·The New England Journal of Medicine·UNKNOWN Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group
Jun 22, 2002·JAMA : the Journal of the American Medical Association·Patrick W J C SerruysUNKNOWN Lescol Intervention Prevention Study (LIPS) Investigators
Nov 30, 2002·Lancet·James ShepherdUNKNOWN PROSPER study group. PROspective Study of Pravastatin in the Elderly at Risk
Dec 20, 2002·JAMA : the Journal of the American Medical Association·UNKNOWN ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. The Antihypertensive and Lipid-Lowering Treatm
Mar 10, 2004·The New England Journal of Medicine·Christopher P CannonUNKNOWN Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction 22 Investigators
Sep 1, 2004·JAMA : the Journal of the American Medical Association·James A de LemosUNKNOWN Investigators
Mar 10, 2005·The New England Journal of Medicine·John C LaRosaUNKNOWN Treating to New Targets (TNT) Investigators
Nov 17, 2005·JAMA : the Journal of the American Medical Association·Terje R PedersenUNKNOWN Incremental Decrease in End Points Through Aggressive Lipid Lowering (IDEAL) Study Group
Aug 11, 2006·The New England Journal of Medicine·Pierre AmarencoUNKNOWN Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) Investigators
Nov 11, 2008·The New England Journal of Medicine·Paul M RidkerUNKNOWN JUPITER Study Group
Mar 21, 2009·Arteriosclerosis, Thrombosis, and Vascular Biology·Joseph L Goldstein, Michael S Brown
Sep 30, 2009·Current Medical Research and Opinion·Leiv OseValerie Arneson
Oct 2, 2009·Diabetes Care·Swapnil N RajpathakPaul M Ridker
Nov 17, 2009·Diabetes Research and Clinical Practice·William L BakerCraig I Coleman
May 14, 2010·Current Opinion in Lipidology·Janine K KruitMichael R Hayden
Nov 12, 2010·Lancet·UNKNOWN Study of the Effectiveness of Additional Reductions in Cholesterol and Homocysteine (SEARCH) Collaborative GroupRory Collins
Apr 2, 2011·Journal of the American College of Cardiology·David D WatersPhilip Barter
Jun 23, 2011·JAMA : the Journal of the American Medical Association·David PreissKausik K Ray
Dec 30, 2011·International Journal of Cardiology·Kwang Kon KohEak Kyun Shin
Jan 11, 2012·Archives of Internal Medicine·Annie L CulverYunsheng Ma
Dec 12, 2012·Journal of the American College of Cardiology·David D WatersTerje R Pedersen
Feb 27, 2013·The Cochrane Database of Systematic Reviews·Fiona TaylorShah Ebrahim
Nov 1, 2013·American Journal of Cardiovascular Drugs : Drugs, Devices, and Other Interventions·Eliano Pio NavareseHarry Suryapranata
Nov 19, 2013·Journal of the American College of Cardiology·Neil J StoneUNKNOWN American College of Cardiology/American Heart Association Task Force on Practice Guidelines

❮ Previous
Next ❯

Citations

Nov 2, 2019·Current Atherosclerosis Reports·Anandita AgarwalaSalim S Virani
Nov 28, 2019·Cardiovascular Drugs and Therapy·Veronica AzemawahMehrnoosh Hashemzadeh
Mar 30, 2019·Cardiovascular Diabetology·Ricardo J Esper, Roberto A Nordaby
Jul 8, 2020·International Journal of Molecular Sciences·Unai Galicia-GarciaCésar Martín
Nov 5, 2019·Journal of the Neurological Sciences·Johanna Andrea Gutiérrez-Vargas, Gloria Patricia Cardona-Gómez

❮ Previous
Next ❯

Related Concepts

Related Feeds

CV Disorders & Type 2 Diabetes

This feed focuses on the association of cardiovascular diseases in patients with type 2 diabetes.

Cardiovascular Disorder in Diabetes

Diabetes is associated with an increased risk of cardiovascular disorders and heart failure. Discover the latest research here.